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Cryptic Splicing at a Non-Consensus Splice-Donor in a Patient
with a Novel Mutation in the Plakophilin-1 Gene
To the Editor:
Desmosomes are intercellular junctions that serve to anchor
intermediate filaments in one cell to neighboring cells,
creating a supercellular scaffold imparting mechanical
strength to cells and tissue. The desmosomal complex
contains members of the desmosomal cadherin, the plakin
and the armadillo repeat protein families (McMillan and
Shimizu, 2001). Plakophilin-1 (PKP1) is an armadillo protein,
mainly concentrated in the suprabasal layers of the
epidermis (Schmidt et al, 1997). PKP1 may interact either
directly with intermediate filaments or indirectly through
plakoglobin and desmoplakin (Kowalczyk et al, 1999),
hence playing a crucial role in the maintenance of
desmosome–intermediate filament interactions. This role is
illustrated by the human phenotype caused by homozygous
null and splice site mutations in plakophilin-1, ectodermal
dysplasia-skin fragility (McGrath) syndrome (McGrath et al,
1997, 1999; Whittock et al, 2000; Hamada et al, 2002). The
syndrome is characterized by skin fragility, disabling
cracking palmoplantar keratoderma, sub-total hypotricho-
sis, and nail dystrophy. The skin shows suprabasal
thickening of the epidermis and loss of cell cohesion in
the intermediate layers of the epidermis (acantholysis).
Nearly all patients reported so far were severely affected
children suffering from almost complete hair loss and
extensive skin erosions induced by light trauma. Reduced
sweating was also reported (McGrath et al, 1997). Hamada
et al (2002) recently reported a patient with a somewhat
milder phenotype of relatively few, late-onset skin erosions,
late-onset palmoplantar keratoderma, and alopecia. In this
patient, low residual expression of full-length PKP1 appar-
ently reduced the severity of his disease. Here we report a
patient whose phenotype is even milder and describe the
molecular mechanisms that may contribute to it. Informed
consent was obtained from the patient, Ethical Committee
approval according to the Helsinki guidelines was obtained
prior to this investigation.
A 33-y-old Dutch male suffered, since birth, from
vulnerability of the skin and recurrent cutaneous infections.
Ever since childhood he complained of extreme plantar
hyperkeratosis that hampered walking. No living relatives
could be located as the patient did not know his parents. He
presented with sharply demarcated, oozing erythematous
lesions predominantly on the buttocks and in the inguinal
area (Fig 1a). The lesions were induced by shearing trauma
and often showed secondary infection. There was no
blistering. The scalp hair was dark, thick and curly and
could easily be plucked without pain (Fig 1b). Eyebrows,
eyelashes, pubic and axillary hair were sparse. Marked
cracking hyperkeratosis was present on the soles of the feet
(Fig 1c). All toenails and some of the fingernails were
thickened and showed subungual hyperkeratosis. The
palms displayed circumscribed hyperkeratoses. In addition,
follicular hyperkeratoses were found on the thorax. Ophthal-
mologic examination showed stellate opacities of both
lenses. The teeth were normal and sweating was not
impaired. Histological examination of three biopsies ob-
tained from erosive lesions of the axillary and inguinal region
consistently displayed suprabasal splitting and acantholy-
sis. Acantholysis was also observed within the hair follicles
of the scalp. Electron microscopic examination of a skin
biopsy obtained from the elbow demonstrated clumping of
tonofilaments in keratinocytes (not shown).
We diagnosed the patient with ectodermal dysplasia-skin
fragility (McGrath) syndrome, and sequenced the coding
regions and exon boundaries of the plakophilin-1 gene on
genomic DNA to confirm the diagnosis (PCR primer
sequences and conditions available on request). A homo-
zygous G to A transition in the splice donor site of exon 9
(1680þ 1G4A, IVS9þ1G4A) was identified that putatively
abolishes the splice donor site (Fig 2a) and an XcmI
restriction site. The mutation was not detected by restriction
analysis in 168 control alleles from the Dutch population. No
other PKP1 nucleotide variations were detected in the
patient. Transcriptional analysis of RNA isolated from a skin
biopsy (RNEasy kit, Qiagen, Hiden, Germany) by RT-PCR
(Superscript first-strand synthesis system, Invitrogen, Bre-
da, the Netherlands) and subsequent sequencing (BigDye-
Deoxy Terminator kit, Applied Biosystems, Foster City, CA)
identified transcripts with retention of intron 9, besides a
smaller alternative-splicing product (Fig 2b). The latter
product results from splicing at a non-consensus (GC)
cryptic splice donor site within exon 9, allowing in-frame
splicing to exon 10 with the loss of 45 nucleotides from the
30 end of exon 9 (Fig 2b,c). The predicted protein product
lacks 15 amino acids in the sixth armadillo repeat, but will
otherwise be intact as a  78.5 kDa product (Fig 2c).
Immunohistochemical staining of skin biopsies using a
monoclonal antibody directed against plakophilin-1 con-
firmed protein expression. Punctate PKP1 staining through-
out most layers of the epidermis was seen (Fig 1d).
Expression seemed to be strongest in the suprabasal
layers. In healthy individuals, the expression pattern was
essentially identical (Fig 1d). Using Western blottingAbbreviation: PKP1, plakophilin-1
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(NuPAGE high-performance gel and blotting system, In-
vitrogen) we were able to confirm expression of the
truncated protein (data not shown).
These results suggest that the relatively mild phenotype
observed in our patient is the result of a partial PKP1 protein
‘‘rescue’’. A cryptic splice donor site drives in-frame splicing
of approximately half of exon 9 to exon 10, consequently
allowing expression of a shortened but partially functional
protein. Immunohistochemical examination of skin biopsies
in our patient confirms the presence of the protein. The
phenotype may be explained by either insufficiency of
expressed shortened protein, or the armadillo repeat dele-
tion may interfere with the interactions between plakophilin-1
and its partner molecules.
Use of cryptic (alternative) GC splice sites has been
observed to account for 0.5%–1% of instances of splicing
in wild-type genes (Burset and Guigo 1996; Burset et al,
2000, 2001). Its occurrence has not yet been described for
plakophilin-1. Use of GC-cryptic splice sites in alternative
splicing elicited by abolishment of the normal splice donor
site is probably a rare event in human disease, as we have
not been able to find similar instances in the literature.
Recently, Hamada et al (2002) published a patient suffering
from a mitigated form of McGrath syndrome, induced by a
donor splice site mutation (2021þ 1G4A) causing in-frame
cryptic splicing among other splicing products. How-
ever, while their patient presents complete hypotrichosis,
our patient suffers only slight hair loss. The phenotype
described here is therefore even milder.
In conclusion, we describe a patient suffering from
ectodermal dysplasia-skin fragility syndrome caused by a
novel splice site mutation. His phenotype may be amelio-
rated through partial protein rescue made possible by use
of a non-consensus cryptic GC splice site, a phenomenon
Figure 1
Phenotype of the patient and immunohistochemical analysis of the skin. (a) Erosive skin lesions on the buttocks. (b) Relatively normal amount of
scalp hair; note the woolly hair. (c) Pronounced plantar hyperkeratosis with fissures and nail dystrophy. (d) Immunohistochemical analysis of PKP-1
expression in patient skin (mt) and in normal skin (wt). The patient skin shows pronounced hyperkeratosis and acanthosis with punctate PKP-1
staining throughout the epidermis (  5). Normal skin shows a similar membrane staining (  5). Insets:  20 enlargement. Slides were subjected to
a standard peroxidase immunostaining procedure with primary mouse IgG1 anti-PKP1 monoclonal antibody (Clone PP1-5C2, Progen Biotechnik
GmBH, Heidelberg, Germany) and VECTASTAIN ABC reagent (Vector Laboratories, Burlingame, CA).
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that has not been previously described in the context of
human disease. Our results point to unexpected facets of
splicing regulation in the perspective of disease-causing
mutations.
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Figure 2
Mutation analysis and RT-PCR results. (a) Sequence traces showing the splice site mutation (mt¼mutant, wt¼wild-type control). (b) Analysis of
splicing products using RT-PCR with primers in PKP-1 exons 8 and 11 (8F: AGGTGCCCACCCGCTACC; 11R:AGCAGGCCGAGGACAAGATG) on
patient skin RNA (mt, lane 2) and on control skin RNA (wt, lane 3). Splicing products are schematically depicted on the left with the upper DNA band
(lane 2) representing the splice product with intron 9 included (1759 bp) and the lower band (lane 2) representing the product on the right resulting
from the cryptic splicing (477 bp). The wild-type product (lane 3) is 522 bp. Lane 1: molecular weight marker. PCR was performed according to the
manufacturer’s standard conditions (Invitrogen) with the initial step 90 s at 941C, then 35 cycles 30 s at 941C, 30 s at 631C, 60 s at 721C and a final
step of 420 s at 721C. (c) Schematic representation of the protein sequence resulting from RNA splicing using the cryptic GC site compared to the
wild-type sequence. The wild-type (wt) splice site (underlined) becomes non-functional by the splice site mutation (IVS9þ1G4A) resulting in the use
of a non-consensus GC cryptic splice site (underlined) within PKP-1 exon 9. After protein translation, the mt PKP-1 protein is effectively 15 amino
acids internally shortened compared with the wt protein (lower panel).
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